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Abstract
The inhibitory receptor FcγRIIb regulates B-cell functions. Genetic studies have
associated Fcgr2b polymorphisms and lupus susceptibility in both humans and
murine models, in which B cells express reduced FcγRIIb levels. Furthermore,
FcγRIIb absence results in lupus on the appropriate genetic background, and
lentiviral-mediated FcγRIIb overexpression prevents disease in the NZM2410 lupus
mouse. The NZM2410/NZW allele Fcgr2b is, however, located in-between Sle1a and
NZW
Sle1b, two potent susceptibility loci, making it difficult to evaluate Fcr2b
independent contribution. By using two congenic strains that each carries only Sle1a
NZW
(B6.Sle1a(15–353)), or Fcr2b
in the absence of Sle1a or Sle1b (B6.Sle1(111–
NZW
148)), we show that the Fcr2b
allele does not upregulate its expression on
germinal center B cells and plasma cells, as does the C57BL/6 allele on
B6.Sle1a(15–353) B cells. Furthermore, in the absence of the flanking Sle1a and
NZW
Sle1b, Fcr2b
does not produce an autoimmune phenotype, but is associated with
an increased number of class-switched plasma cells. These results show that while a
lower level of FcγRIIb does not by itself induce the development of autoreactive B
cells, it has the potential to amplify the contribution of autoreactive B cells induced by
other lupus-susceptibility loci by enhancing the production of class-switched plasma
cells.

This article has been peer reviewed. It is the authors’ final version prior to publication in Genes and Immunity
(2007), 1–9, 2007. The published version is available at http://www.nature.com/gene. Copyright 2007 Nature
Publishing Group.
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Introduction
Both forward and reverse genetic approaches in lupus patients and in murine models
have shown a high level of complexity in the mechanisms by which genetic variation
1
contributes to lupus susceptibility. A number of linkage and association studies have
associated the Fcγ receptors (FcgRs) with lupus susceptibility in both humans and
mice. Among the FcγRs, FcγRIIb plays a unique role in inducing inhibitory signals in
2

B cells upon immune complex binding. In humans, a -343 G/C promoter
polymorphism and a Ile232Thr trans-membrane polymorphism, both associated with
3
loss of function, have been associated with lupus. The strength of the association
between each of these polymorphisms and disease varied among populations, most
likely due to interactions with other susceptibility alleles segregating differently
among these populations. Functionally, two recent studies have reported that lupus
patients present a defective upregulation of FcγRIIb expression in selected late B4,5
cell developmental stages, namely, memory B cells and plasma cells (PC). In the
mouse, FcγRIIb is required for the maintenance of systemic tolerance on a C57BL/6
(B6) background,6 and a B-cell receptor l transgenic model has suggested that it
constitutes a checkpoint at the post-germinal center (GC)/plasma cell stage.7
Several lupus-prone strains show reduced FcγRIIb levels attributed to a promoter
region polymorphism for NZB, BXSB and MRL.8,9 However, using B6.Sle1/NZW and
NZW mice, we have recently shown that failed upregulation of FcγRIIb on GC B cells
is not associated with the promoter region polymorphism, but rather with additional
polymorphisms in the putative regulatory regions 3 and 4 in the third intron shared by
both NZB and NZW alleles.10 A direct demonstration of the involvement of FcγRIIb in
lupus pathogenesis was dramatically demonstrated in both the NZM2410 and BXSB
models, in which full disease abrogation was achieved by partial restoration of
FcγRIIb expression on hematopoeitic cells.11
The B6.Sle1 congenic interval corresponds to the 37 cM long telomeric end of
12
chromosome 1 derived from the NZM2410/NZW genome. The location within this
interval of the Fcgr2b gene makes this the primary observed on B6.Sle1 GC B
10
cells. However, it is not clear whether the polymorphisms in the FcγRIIb NZW allele
alone are responsible for the perturbed expression of FcγRIIb on GC B cells in
B6.Sle1 mice or whether other susceptibility genes located within the Sle1 interval
might act epistatically in producing this altered expression. In addition, Fcgr2b is
located between Sle1a and Sle1b, and we have reported that a congenic strain
B6.Sle1(111–148) that contains Fcgr2b but lacks both Sle1a and Sle1b does not
13
produce autoantibodies. The B6.Sle1(111–148) strain contains in addition to
NZW
Fcgr2b
a number of genes of NZW origin, including two FcR homolog genes
NZW
Fcrla and FcRlb. It however allows the evaluation of Fcgr2b
independently from
NZW
Sle1a and Sle1b. In the present study, we report that Fcgr2b
fails to upregulate

on GC B cells independently from Sle1a and Sle1b, and that it is associated with a
greater number of class-switched PCs in the spleen and bone marrow (BM).
Results
Perturbed upregulation of FcγRIIb expression on GC B cells in B6.Sle1 mice
10

As previously described, we have established an operative definition of GC B-cell
phenotype for flow cytometry using peptide nucleic acid (PNA), in combination with
hi
anti-B220 and anti-IgD. Based on B220 and PNA staining, we first separated B220
neg
mature B cells consisting of both PNA þ and PNA (rectangular gate, Figure 1a, left
panel) populations from total lymphocytes obtained from sheep red blood cells
(SRBC)-immunized C57BL/6 (B6) mice on day 9 of the immune response. We then
hi
neg
hi
neg
defined B220 PNA IgD þ and B220 PNA þ IgD cells as non-GC and GC B
cells, respectively (rectangular gates, Figure 1a, right panel).
Using these definitions, we first measured the levels of FcγRIIb on splenic B-cell
subpopulations, by performing four-color flow cytometry analysis from B6 and
-/B6.Sle1 mice on day 9 of the anti-SRBC response. Fcgr2b-deficient (B6.RIIB ) mice
were used as negative controls. The mAb 2.4G2 that recognizes the extracellular
domains of both FcγRII and III was used since no mAb specific for the
NZM2410/NZW/Sle1 FcγRIIb allele (Ly17.1 allotype) is available. As shown in Figure
hi
neg
1b, compared with B220 PNA IgD+ non-GC B cells (red line in histograms), the
hi
neg
levels of 2.4G2 staining were elevated on B220 PNAþ IgD GC B cells (blue line in
histograms) in B6 mice (Figure 1b, lower left panel) while background levels of
-/staining on both populations of B cells were observed in B6.RIIB mice (Figure 1b,
10
right most panel). As previously described, and illustrated in Figure 1b, in contrast
to splenic GC B cells in B6 mice (lower left panel), we found little or no elevation of
2.4G2 staining levels on B6.Sle1 splenic GC B cells (blue line in histograms for
hi
neg
B220 PNAþ IgD cells, lower middle panel) as compared with non-GC B cells (red
line in histograms, lower middle panel).
We also investigated whether the altered expression of FcγRIIb we observed by flow
cytometry on B6.Sle1 GC B cells was apparent on GC B cells and follicular dendritic
cells (FDCs) were defined histologically. Parallel spleen sections obtained on day 9
-/post-SRBC immunization of B6, B6.Sle1 and B6.RIIB mice were stained with 2.4G2
and anti-IgD (Figure 1c, left panels) and FDC-M1 and GL7 (Figure 1c, right panels)
to evaluate the expression of FcγRIIb on GC B cells and FDCs, respectively.
Although 2.4G2 staining in B6 and B6.Sle1 GC FDC-rich regions was comparable,
this staining was undetectable in B6.Sle1 GC areas deficient in FDCs. The
background level of staining in both FDC-rich and FDC-poor regions of GCs in
-/B6.RIIB mice indicated that FcγRIII is not expressed at levels detectable with 2.4G2
on these cells. Together, these results confirmed our recently reported data showing

a defect in the upregulation of FcγRIIb expression on GC B cells in autoimmune10
prone B6.Sle1 mice.
The Fcgr2b allele in B6.Sle1(111–148) is of NZW origin
13

We have already excluded Fcgr2b from the Sle1a and Sle1b intervals, but both
NZW
these loci could interact with the Fcgr2b
allele and contribute to the failed FcγRIIb
upregulation in Sle1 GC B cells. To test this hypothesis, we genotyped the two
overlapping strains represented in Figure 2a: B6.Sle1a(15–353), previously
14
associated with autoreactive T cells and B6.Sle1(111–148), previously described
13
as not producing autoantibodies. A third intron deletion (Figure 2b) specific to the
B6
10
NZW allele determined that the Sle1a(15–353) interval contained the Fcgr2b
allele, mapping the telomeric recombination breakpoint between D1MIT270
(included) and Fcgr2b (excluded). In contrast, the Sle1(111–148) interval contained
NZW
the Fcgr2b
allele, placing the telomeric recombination breakpoint between the
Fcgr2b third intron (included) and D1MIT146 (excluded). We have not determined
yet the exact location of the recombination breakpoint, and whether it is telomeric to
the Fcgr2b promoter (Figure 2a, inset). The two strains also differed by their
13
centromeric region centered on the D1MIT15 marker, where Sle1a was mapped.
The NZW origin of Fcgr2b in the B6.Sle1(111–148) strain was confirmed at the
protein level. The mAb K9.361, which is specific for the FcγRIIb Ly17.2 allotype, was
used to measure the levels of FcγRIIb on B-cell subpopulations. Four-color flow
cytometry analysis of splenocytes obtained on day 9 of the anti-SRBC response
revealed background levels of K9.361 staining on B6.Sle1(111–148) B-cell
subpopulations as compared to the strong staining of B6 control and B6.Sle1a(15–
353) GC (blue line in histograms) and non-GC (red line in histograms) B cells (Figure
3a). In addition, the levels of K9.361 staining on both B6 and B6.Sle1a(15–353) GC
B cells were at least fivefold higher compared with their non-GC counterparts. We
also performed histological analysis (Figure 3b) of spleen sections obtained on day 9
of the anti-SRBC response by staining with anti-IgD (red) and K9.361 (green). While
neg
elevated levels of K9.361 staining were seen on IgD B cells in B6 and
B6.Sle1a(15–353) GCs, this staining was undetectable in B6.Sle1(111–148) GCs,
further supporting the conclusion that the Fcgr2b allele in B6.Sle1(111–148) mice is
not of B6 but of NZW/NZM2410 origin.
Failed upregulation of FcγRIIb on B6.Sle1(111–148) GC B cells
Using the protocol described above, we evaluated the levels of FcγRIIb on GC and
non-GC B-cell populations in splenocytes obtained on day 9 of the anti-SRBC
responses of B6, B6.Sle1a(15–353) and B6.Sle1(111–148) mice (Figure 4a). In
contrast to B6 GC B cells (blue line in histograms, lower left panel), little or no
elevation of 2.4G2 staining levels was observed on B6.Sle1(111–148) GC B cells
(blue line in histograms, lower right panel). Interestingly, however, we found levels of
2.4G2 staining on B6.Sle1a(15–353) GC B cells at least eightfold higher than that on

non-GC B cells (Figure 4a, lower middle panel), analogous to that observed on B6
splenic GCs.
To corroborate these findings, we next performed histological analysis as described
above in Figure 1c. As shown in Figure 4b, two sets of parallel spleen sections from
each genotype were stained. Although 2.4G2 staining in the FDC-rich regions in
GCs of all three strains was comparable, elevated levels of 2.4G2 staining was
observed in the FDC-poor regions of B6 and B6.Sle1(15–353) GCs as compared to
substantially lower or undetectable levels of staining in these regions in
B6.Sle1(111–148) GCs (shown in arrows, right most column), analogous to that
observed in B6.Sle1 GCs (Figure 1c).
-/-

Staining of B6.RIIB mice indicated that the mAb 2.4G2 predominantly detects
FcγRIIb expression on GC B cells. Nonetheless, since this mAb recognizes the
extracellular domains of both FcγRIIb and FcγRIII, a fraction of the 2.4G2 staining
differences observed in B6.Sle1 or B6.Sle1(111–148) GCs could have resulted from
neg
altered expression of FcγRIII. Therefore, we sorted B220 þ PNA þ IgD GC B cells
obtained on day 9 of the SRBC response and measured Fcgr2b mRNA levels via
real-time RT-PCR. Fcgr2b mRNA levels in B6.Sle1(111–148) GC B cells were
threefold lower than those in B6 control and B6.Sle1(15–353) GC B cells (Figure 4c).
In total, these data indicated a defect in the upregulation of FcγRIIb expression on
B6.Sle1(111–148) GC B cells similar to that observed in the B6.Sle1 strain.
NZW

The Fcgr2b

allele is associated with an increased IgG production

We screened a new cohort of 10-to 12-month-old B6.Sle1(111–148) mice and
confirmed as previously reported that these mice do not produce anti-chromatin or
anti-dsDNA antibodies (data not shown). To further determine the functional
NZW
consequences of the expression of the Fcgr2b
allele, we compared antibody
levels in SRBC-immunized mice. There was no significant difference between the
three strains in levels of either SRBC-specific IgM or total IgM (Figures 5a and d). In
contrast, B6.Sle1(111–148) mice produced significantly higher levels of SRBCspecific IgG and total IgG (Figures 5b and e). This resulted in a significantly skewed
IgG/IgM ratio for both the response to the T-dependent antigen and the total
circulating immunoglobulin (Figures 5c and f).
We have recently demonstrated that Fcgr2b deficiency regulated the production of
autoreactive primary anti-production body-forming cells (AFCs) by BCR transgenic B
15
cells independent of GC events. We, therefore, compared the effect of the Fcgr2b
NZW and B6 alleles on AFC formation 6 and 14 days after SRBC immunization. At 6
days in the spleen and 14 days in the BM, FcγRIIb expression on AFCs mirrored that
on GC B cells with a significantly reduced level associated with the NZW allele
(Figure 6a). Surface IgM expression on both CD138+ B220+ plasmablasts and
-/lo
CD138+ B220 PC was significantly lower in B6.Sle1(111–148) than in either B6 or
B6.Sle1a(15–353) mice (data not shown). Consistent with the surface expression,
the percentage of intra- cellular IgM+ was also significantly lower in both splenic and

BM PCs at 6 and 14 days post immunization (p.i.) (Figure 6b), while the percentage
of intracellular IgG+ PCs was significantly higher in B6.Sle1(111–148) spleens at 6
-/lo
days p.i. (Figure 6c). Finally, the percentage of total CD138+ B220 PCs was
significantly higher in B6.Sle1(111–148) spleens at 6 and 14 days p.i. and BM 6 days
p.i. (data not shown). These results were confirmed by the presence of a larger
number of IgG+ AFCs in the spleen (although it did not reach statistical significance)
and the BM (Po0.03) at 6 days p.i. in B6.Sle1(111–148) mice (Figure 6d). The same
type of analysis was performed on mice following secondary immunization, and we
did not observe any specific difference in B6.Sle1(111–148) mice (data not shown).
NZW
Together, these data suggest that Fcgr2b
regulates the primary AFC pathway by
increasing their number and by accelerating class switching.

Discussion
We have used NZM2410/NZW-derived congenic strains to analyze the phenotypes
NZW
associated with the Fcgr2b
allele independently from the flanking lupus susceptibility loci Sle1a and Sle1b. We have used a combination of genomic, transcriptional
and histological methods to show that the 2–3 Mb congenic interval of B6.Sle1(111–
148) contains the NZW allele of Fcgr2b, while the strain B6.Sle1a(15–353) that we
have used previously to analyze Sle1a phenotypes contains the B6 allele of Fcgr2b.
10

As we have previously described for the NZW and B6.Sle1 strains, B6.Sle1(111–
148) B cells fail to upregulate FcγRIIb at the GC stage, indicating that this phenotype
does not require the expression of the Sle1a and Sle1b loci. The B6.Sle1(111–148)
interval contains 15 other transcripts of known genes (www.ensembl.org/
Mus_musculus/ based on the NCBI m36 mouse assembly). At least 12 of these
genes are shared with B6.Sle1a(15–353) and can, therefore, be excluded from
impacting Fcrg2b expression. There are, however, two FcR homolog genes Fcrla
17
16
(Freb2) and Fcrlb (FcRY or Freb1) that are contained in the B6.Sle1(111–148)
interval, and potentially not in the B6.Sle1a(15–353) interval since they are situated
in the region of recombination between the D1MIT270 and D1MIT147 markers.
These two FcR family members are differentially expressed on B cells, including GC
18,19
B cells, but their function is yet unknown.
Interestingly, FCRL3,a member of this
family in humans, is associated with RA and other autoimmune conditions, including
20
lupus. We are currently investigating whether one or both of these genes present
allelic differences between NZW and B6. If it were the case, it would be possible that
these genes could indirectly regulate Fcrg2b on GC B cells. The most likely
explanation, however, is that the failure to upregulate Fcgr2b expression on GC B
cells is regulated in cis by the Fcgr2b NZW allele.
In spite of the low expression of FcγRIIb on GC B cells, the number and size of GCs
were equivalent between B6.Sle1(111–148) and B6 mice. We have found, however,
that B6.Sle1(111–148) mice produced significantly more anti-SRBC IgG and total
IgG, which was correlated with a greater number of primary AFCs that
downregulated surface and intracellular IgM in favor of IgG. We have confirmed

21

recent results showing FcγRIIb expression on PC, but contrary to the other
autoimmune strains NZB and MRL in which FcγRIIb is virtually absent on the PC
surface, the NZW allele is associated with only a modest reduction of expression on
PCs. Future experiments will have to be performed to assess whether this modest
reduction is sufficient to decrease PC turnover through decreased apoptosis in
NZW
21
Fcgr2b
-carrying mice, as it has been shown for Fcgr2b-deficient mice.
Interestingly, the kinetics of FcγRIIb expression on PC as well as the absence of
NZW
Fcgr2b
-specific phenotype in secondary immune responses corroborates our
15
previous findings that this receptor regulates allele does not result by itself in the
production of primary T-dependent immune responses.
NZW

Overall, our results indicate that Fcgr2b
functions an Fcgr2b hypomorph in
regulating AFC numbers and class switching independent of GC reactions. This
concurs with previous findings that showed that an Fcgr2b deficiency allows the
7,10
accumulation of autoreactive PC. Interestingly, however, the Fcgr2b NZW allele
does not result by itself in the production of autoreactive B cells, but acts as a
modifier of the fate of autoreactive B cells induced by the expression of other as loci.
It is not clear to what extent primary AFC foci contribute to systemic autoimmunity.
However, at least in the MRL/lpr model, autoreactive B cells expand and
22
hypermutate outside of GCs, which suggests that primary AFCs constitute a key
regulatory pathway in the maintenance of B-cell tolerance. We are in the process of
testing whether a similar GC ‘bypass’ also occurs in the NZM2410 strain, and what
role, if any, Fcgr2b plays in this context.
23

We have previously documented the highly interactive nature of the Sle1 loci, and
we have specifically shown that the interval including Sle1a, Sle1b and the intervening region resulted in autoimmune phenotypes that were much stronger than the
NZW
simple additive effects of Sle1a plus Sle1b. We speculate that Fcgr2b
contributes
to these epistatic effects. In addition, we have previously shown that both NZM2410
24
and NZW mice present an accumulation of PC in the spleen. Although we were not
able to map the entire phenotype to any single Sle locus, it is also temping to
speculate that reduced FcγRIIb expression may contribute to this phenotype, as
suggested by our data in Figure 6. Interestingly, close examination of our results in
Figures 5 and 6 suggests that Sle1a also impacts the immune response to SRBC
immunization, including the number of class-switched PCs. Detailed studies of the
NZW
interaction between Fcgr2b
and the other Sle loci in the context of plasma cell
development will be necessary to fully understand how the restoration of normal
11
FcγRIIb expression on NZM2410 B cells was sufficient to abrogate disease.

Materials and methods
Mice and immunization
The B6.NZM2410-Sle1 (B6.Sle1), B6.NZM2410-Sle1a(15– 353) (B6.Sle1a(15–353))

and B6.NZM2410-Sle1(111–148) (B6.Sle1(111–148)) mice have already been
12,13
described.
These mice along with B6 controls were bred at the University of
tm1Rav
Florida Animal Care Center. B6;129S4Fcgr2b
/J (B6.RIIB-/-) were kindly supplied
by Dr Jeffrey Ravetch (The Rockefeller University, New York, NY, USA). All mice
were maintained in a pathogen-free barrier facility and all procedures were approved
by the JU or UF IACUCs. Cohorts of at least three mice per strain were immunized
intra-peritoneally with 200 µl of SRBC diluted 10% v/v in sterile 0.9% saline solution.
Spleens, BM and terminal sera were collected after either 6, 9, or 14 days, as
indicated in the text. All mice were used between 8 and 20 weeks of age, except for
the autoantibody screens, and cohorts of both males and females were used without
significant differences.
Congenic strain genotyping
All available MIT microsatellite markers located within 170 and 173 Mb on
chromosome 1 were screened for polymorphism between B6 and NZW and then
used to assess the haplotype distribution across the B6.Sle1a(15– 353) and
B6.Sle1(111–148) intervals. The NZW or B6 allelic origin of the Fcgr2b gene was
determined with PCR primers designed to detect the 4921–4944 deletion in the third
10
intron (region 4 described by Rahman and Manser ). The sequences were for the
sense primer: 5′-TGCCCCCTCCTCTTATCC and 5′-TGCATGTATGTG CATGTGT
for the antisense primer.
Antibodies and other reagents
Antibodies and other reagents used for flow cytometry and immunohistology
included the following: PE, fluorescein isothiocyanate (FITC) and PE-Texas red-antiB220 (clone RA3–6B2); PE-anti-FcγRII/FcγRIII (clone 2.4G2); PE-anti-IgD (clones
11–26); APC-anti-IgM (clone Igh6); biotin-anti-CD138 (clones 281–282), Streptavidin
(SA)-CyChrome; rat IgG Ab to mouse FDCs (FDC-M1, BD Pharmingen, San Diego,
CA, USA); biotin-anti-IgD (clones 11–26, Southern Biotechnology Associates,
Birmingham, AL, USA); FITC-goat anti-mouse IgG (Southern Biotechnology); SAPE; avidin-Alexa Fluor 488 (Molecular Probes, Eugene, OR, USA); FITC-peanut
lectin (agglutinin, PNA, Vector Laboratories, Burlingame, CA, USA); biotin-(Fab′)2
mouse anti-rat IgG (Jackson Immunoresearch Laboratories, West Grove, PA, USA).
The K9.361 mAb was biotinylated in house from the hybridoma kindly provided by Dr
U Hammerling (Sloan-Kettering Memorial Hospital, New York, NY, USA).
Intracellular staining was performed with BD Pharmingen reagents as recommended
by the manufacturer.
Immunohistology
25

Spleen cryostat sections (5–6 mm) were prepared as described. Immunohistology
was performed using the antibodies listed above and the stained sections were
analyzed using a fluorescence microscopy (Leitz Diaplan, Wetzlar, Germany) and
26
images were captured as described.

Flow cytometry
Four-color flow cytometric analysis was performed on cell suspensions prepared
from spleens of naive and immunized mice stained with multiple combinations of
antibodies listed above. Biotinylated Abs were detected with SA-CyChrome. Stained
cells were analyzed using a Coulter Epics XL/MCL or a Facscalibur (BD
Biosciences) analyzer. Data were analyzed using the FlowJo software (Treestar,
San Carlos, CA, USA).
GC B-cell sorting, RNA extraction and real-time RT–PCR
high

neg

B220 IgD PNA+ GC B cells were sorted using a MoFlo fluorescent activated
high-speed sorter (Dako Cytomation, Glostrup, Denmark). RNA purification, reverse
transcription of RNA, real-time RT-PCR and generating raw RQ (relative
quantification) values for FcγRIIb gene expression in GC B cells were performed as
10
described.
Antibody measurements
All antibodies were detected by enzyme-linked immunosorbent assay (ELISA) in
Immunolon II plates (Dynex, Chantilly, VA, USA). For anti-SRBC antibodies, the
plates were coated with SRBC diluted at 1:1000 in PBS for 1 h at room temperature,
then fixed with 0.5% gluteraldehyde. After blocking (3% BSA, 0.1% gelatin, 3 mM
EDTA), sera were incubated in duplicate at 1:200 dilution for 2 h, and bound IgG
antibodies were detected with an alkaline phosphatase-conjugated goat anti-mouse
IgG antibody (Chemicon International, Temecula, CA, USA) at a 1:1000 dilution.
Total IgM and IgG were detected by sandwich ELISA with sera diluted 1:200 000 as
27
previously described. Anti-chromatin IgG antibodies were detected in 10-to 12month-old mice with plates coated with total histone and dsDNA as previously
28
described.
Enzyme-linked immunospot (ELISPOT) assay
24

AFCs were enumerated by ELISPOT as previously described. Serially diluted RBCdepleted spleen and BM cells were added to multiscreen filter plates (Millipore, MA,
USA) coated with 5 µg/ml goat anti-mouse IgG for 6 h at 37 1C. Bound cells were
detected with HRP-conjugated-anti-IgG (Southern Biotechnology), and developed by
3-amino-9-ethylcarbazole (AEC, Sigma-Aldrich, St Louis, MO, USA). AFCs were
then counted and measured using a Bioreader 4000 Pro-x (BioSys, Germany).
Statistical analysis
Statistical significance was evaluated with the GraphPad Prism 4 software package
and the specific tests were reported in the text (either Bonferroni’s multiple
comparison or variance F tests).
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Figures & Captions

Figure 1
FcγRIIB expression on germinal center (GC) B cells and follicular dendritic cells
(FDCs) in C57BL/6 and b6.Sle1 mice.
(a) Splenocytes from sheep red blood cells (SRBC)-immunized B6 mice on day 9
of the immune response were stained with peptide nucleic acid (PNA), in
combination with anti-B220 and anti-IgD and analyzed by flow cytometry. In
hi
neg
the left panel, B220 and PNA+ /PNA mature cells are shown in the
hi
neg
high
rectangular gate. In the right panel, B220 PNA+ /IgD GC and B220
neg
PNA IgDþ non-GC B cells are shown in two rectangular gates.
hi

(b) Levels of FcγRIIb measured by staining with 2.4G2 (bottom row) on B220
neg
hi
neg
PNA+ /IgD GC (blue histograms) and B220 PNA IgDþ non-GC (red
histograms) B cells are shown for SRBC-immunized B6, B6.Sle1 and B6.RIIB/mice on day 9 of the primary GC response.
(c) (c) Adjacent spleen sections obtained from these mice were stained with
2.4G2 (red) and anti-IgD (green), shown in the left column and FDC-M1 (red)
and GL7 (green), shown in the right column. These data represent those
obtained from three to five mice of each strain.

Figure 2
The B6.Sle1a(15–353) and B6.Sle1(111–148) congenic strains differ by the
B6 or NZW origin of Fcgr2b.
(a) Map of the two congenic intervals with, from top to bottom, the distance in
Mb, the position of key polymorphic microsatellite markers used to define the
interval termini, the position of the Fcgr2b gene and the two intervals. The
gray bars represent the areas of known NZW (NZM2410) derivation, and the
white bars represent the areas of recombination between the NZW and B6
genomes. The boxed inset on the right shows an enlargement of the
telomeric termini between markers D1MIT147 and D1MIT146 relative to the
Fcg2rb transcript.
(b) PCR amplification of the region 4 deletion identifying the NZW allele in
B6.Sle1(111–148) as compared to B6.Sle1a(15–353), which has the B6
alleles.

Figure 3
B6.Sle1(111–148) mice contain a Fcgr2b allele of NZW origin.
(a) Splenocytes from sheep red blood cells (SRBC)-immunized B6, B6.Sle1a(15–
353) and B6.Sle1(111–148) mice obtained on day 9 of the immune response were
stained with peptide nucleic acid (PNA), in combination with anti-B220 and anti-IgD.
Levels of FcγRIIb measured by the mAb K9.361 that specifically stains the Fcgr2b
hi
neg
allele of B6 origin (Ly17.2 allotype) on B220 PNAþ /IgD germinal center (GC)
hi
neg
(blue histograms) and B220 PNA IgDþ non-GC (red histograms) B cells are
shown.
(b) Spleen sections obtained on day 9 of the anti-SRBC response of B6,
B6.Sle1a(15–353) and B6.Sle1(111–148) mice were stained with anti-IgD (red) and
K9.361 (green). These data are representative of at least three mice of each
genotype.

Figure 4
Impaired FcγRIIb expression on B cells and follicular dendritic cells (FDCs) in
B6.Sle1(111–148), but not in B6.Sle1a(15–353) mice.
(a) Splenocytes obtained on day 9 of the anti-sheep red blood cells (SRBC)
response of B6, B6.Sle1a(15–353) and B6.Sle1(111–148) mice were stained and
analyzed, and data are illustrated as detailed in Figures 1a and b.
(b) Two sets of adjacent spleen sections obtained on day 9 of the anti-SRBC
response of B6, B6.Sle1a(15–353) and B6.Sle1(111–148) mice were stained and
illustrated as detailed in the legend to Figure 1c. Substantially lower or undetectable
levels of 2.4G2 staining, in IgD- GL7þ and FDC poor regions in B6.Sle1(111–148)
GCs, are shown by arrows, right most column. These data are representative from
five to seven mice of each genotype. (c) RNA was extracted from FACS-purified
hi
neg
B220 PNA+ /IgD germinal center (GC) B cells obtained on day 9 of the SRBC
response of B6, B6.Sle1a(15–353) and B6.Sle1(111– 148) mice. Raw RQ values of
Fcgr2b expression in B6 (open bar), B6.Sle1a(15–353) (green bar) and
B6.Sle1(111–148) (red bar) GC B cells were obtained via real-time RT-PCR by
setting the RQ value for B6 GC B cells as 1. Real-time RT-PCR amplification was
performed in quadruplet, from which the means and maximum relative quantification
(RQ as calculated by the ABI software) shown as error bars were generated. These
data are representative of pooled samples of two to three mice of each genotype
obtained from three experiments.

Figure 5
IgG production is increased in B6.Sle1a(111–148) mice.
Anti-sheep red blood cell (SRBC) IgM (a) and IgG (b) antibodies, as well as total IgM
(d) and IgG (e) were measured on day 9 after primary immunization in the three
congenic strains. The graphs on the right show the anti-SBRC (c) and total (f)
IgG/IgM ratios. Each symbol represents a mouse. **P < 0.01; ***P < 0.001 from
Bonferroni’s multiple comparison tests.

Figure 6
B6.Sle1(111–148) antibody-forming cells (AFCs) produce less IgM and more IgG
than congenic mice carrying the Fcgr2b B6 allele.
Splenic (graphs on the left) and bone marrow (BM) (graphs on the right) CD138+
B220-/lo plasma cells (PC) were evaluated in 6 and 14 days after sheep red blood
cells (SRBC) immunization.
(a) Surface FcγRIIb expression.
(b) Intracellular IgM expression.
(c) Intracellular IgG expression.
(d) Number of IgG þ AFC measured by ELISPOT. Mean and s.d. of six mice (6 days
p.i.) and three mice (14 days p.i.) per strain. *P < 0.05; **P < 0.01 from Bonferroni’s
multiple comparison tests. Representative flow cytometry histograms gated on
CD138+ B220-/lo PC in the spleen 6 days p.i. are shown on the right, with filled gray

histograms representing C57BL/6, and solid and broken lines representing
B6.Sle1(111–148) and B6.Sle1a(15–353), respectively.

